ArticleBJU international2025
Magnetic resonance imaging for long-term active surveillance biopsy decision-making.
Article in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multicentre validation of the PRECISE scoring system for prostate MRI during active surveillance.European radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo evaluate whether long-term magnetic resonance imaging (MRI) findings, alone or in combination with prostate-specific antigen (PSA) density or the result of prior surveillance biopsies, could be used to omit biopsies occurring after patients have been on active surveillance (AS) for ≥5 years. PATIENTS AND
methodsAnalysis of a single-institution AS cohort of patients with Grade Group (GG) 1 prostate cancer who underwent a scheduled 6-year MRI and biopsy. Multivariable logistic regression was used to test the association between the Prostate Imaging-Reporting and Data System (PI-RADS) score, PSA density, status of prior AS biopsy, and reclassification to GG ≥2. We then analysed how many GG ≥2 cancers would be missed if the 6-year biopsy was avoided based on significant predictors.
resultsIn all, 49 of 221 men (22%) were reclassified to GG ≥2. PSA density and PI-RADS scores 4-5 were significant predictors; a prior negative AS biopsy was inversely associated with GG ≥2. The risk of missing GG ≥2 if the 6-year biopsy is omitted in men with an unsuspicious MRI (PI-RADS 1-2) was 12% (95% confidence interval [CI] 5.3-19%). After testing combinations of MRI findings, PSA density, and the status of the prior biopsy, we found the lowest risk of GG ≥2 in patients with a prior negative biopsy and PSA density of <0.10 ng/mL/cc (5.3%, 95% CI 1.5-10%).
conclusionsAn unsuspicious MRI at 6 years is not enough alone to omit the 6-year AS biopsy under current guidelines. Combining MRI findings, PSA density, and prior negative AS biopsies is a promising strategy to tailor surveillance intensity. Our findings should be replicated in larger cohorts prior to implementation in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.